The Ministry of Health, Labor and Welfare (MHLW) on December 18 presented a proposal to define the scope of products…
HOME > TOP STORIES
TOP STORIES
-
BUSINESS Over 60% of Drug Makers Cut New Grad Hires in FY2018, Otsuka Tops List Again: Tally
May 8, 2018
-
BUSINESS Competition Heating Up for HIF-PH Inhibitors; Astellas Expected to Be First with Filing Likely in FY2018
May 7, 2018
-
BUSINESS Japan to Join Jardiance Study for CKD under Collaboration between Boehringer, Lilly, and Oxford
May 2, 2018
-
BUSINESS Olmetec Sales Nosedive 67.8% in North America in FY2017: Daiichi Sankyo
May 1, 2018
-
BUSINESS Bayer Japan Chief “Disappointed” at PMP Removal for Xarelto, Shows Eagerness for Add’l Indications
April 27, 2018
-
REGULATORY Imfinzi Sails through MHLW Panel, Now in Line for Stage III NSCLC Nod
April 26, 2018
-
ORGANIZATION PhRMA/EFPIA Say Humira, Jevtana, Xarelto Lost Eligibility under New PMP, Innovation Not Appropriately Defined
April 26, 2018
-
BUSINESS Takeda, Shire Reach Preliminary Deal, Extend Takeover Deadline to May 8
April 25, 2018
-
BUSINESS Takeda Makes Fifth Pitch for Shire Buyout as Deadline Looms
April 25, 2018
-
BUSINESS Novartis Seeks Japan Approval for Kymriah, Will Outcome-Based Model Be Put in Place?
April 24, 2018
-
ACADEMIA Clinical Trials for Mitochondrial Disease Heating Up with AMED’s Support; Filing for First Hyperlactacidemia Drug Expected in 2020
April 23, 2018
-
BUSINESS Takeda Sweetens Bid for Shire, Ups Cash Component
April 23, 2018
-
BUSINESS Takeda in Talks with Shire after 3 Buyout Proposals Rejected
April 20, 2018
-
TRENDS Industry Group Anticipates New Demand for Contract Reps after Current Phase of Downsizing by Drug Makers
April 20, 2018
-
BUSINESS Tecentriq Now in PD-1/L1 NSCLC Showdown, Lynparza Also Hits Japan Market
April 19, 2018
-
ACADEMIA Physicians Association Initiates Large-Scale Study to Directly Compare DPP-4 Inhibitors to SGLT2 Inhibitors, Determine “Optimal Patients” for Each
April 19, 2018
-
BUSINESS Another Huge Seller Re-Pricing Won’t Hit Opdivo Unless 195 Billion Yen Sales Reached: Ono Chief
April 18, 2018
-
BUSINESS Sumitomo Dainippon Reorganizes Drug Discovery Research System; Accelerating Decision-Making: Pres.
April 18, 2018
-
REGULATORY Pharma Leaders Air Grievances on Pricing Reform Package at New MHLW Confab
April 17, 2018
-
BUSINESS Takeda CEO Eager to Lure More Partners to Shonan iPark, Says Diversity Is Source of Creativity
April 16, 2018
ページ
Eli Lilly’s Kisunla (donanemab) will join the Japanese reimbursement list on November 20, with a health ministry panel giving the…
Will an “off-year” drug price revision happen in April 2025 or not? Over the last week, expectations have been up…
For 25 years, Morunda has been interviewing leaders in Japan’s pharmaceutical and medical device industry. Most country managers typically come from a commercial background, rooted in sales and marketing. It’s rare to find country managers who come from finance or…
A Japanese health ministry panel discussing the generic industry structure on May 22 put together a report in which it…
A Japanese health ministry study group focused on pharmaceutical regulations on March 21 agreed on a policy to encourage the…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…
The Japanese health ministry’s expert panel tasked to discuss comprehensive policies for the rapid and stable supply of pharmaceuticals generally…
Authorized generic (AG) strategies taken by innovative drug makers might help soften the impact of generic competition in their businesses but such tactics might also accelerate the application of “G1”/“G2” price cuts for their off-patent brand-name medicines, a Jiho tally…
Japan’s health ministry announced new NHI prices to be applied in April under the FY2022 drug price revision in the official gazette on March 4, with the earlier application of so-called “G1” price cuts to be implemented for the first…